Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-04-2015 | Original Article - Cancer Research

Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer

Authors: Yan-Long Liu, Xu Gao, Yang Jiang, Gan Zhang, Zi-Cheng Sun, Bin-Bin Cui, Yan-Mei Yang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2015

Abstract

Background and objectives

Enhancer of zeste 2 (EZH2), embryonic ectoderm development (EED), and suppressor of zeste 12 homolog (SUZ12), the key component of polycomb repressive complex 2, are of great importance in human cancer pathogenesis. This study was designed to investigate the clinical and prognostic significances of EZH2, EED and SUZ12 in colorectal cancer (CRC) patients.

Methods

The expression of EZH2, EED and SUZ12 mRNA was evaluated in 82 primary CRC and paired non-cancerous mucosa samples by qRT-PCR.

Results

We found that overall EZH2, EED and SUZ12 mRNA expression in the CRC tissues was significantly increased than in the non-cancerous tissue (p < 0.05). Increased EZH2, EED and SUZ12 mRNA expression was directly correlated with primary tumor size, regional lymph node metastases, distant metastasis and AJCC stage. Furthermore, CRC patients with higher level of EED, SUZ12 or EZH2 showed a worse disease-free survival (DFS) (p < 0.01). In multivariate analysis, the increased EZH2 expression may be a risk factor for the patients’ 3-year DFS (HR 2.517; 95 % CI 1.104, 5.736; p = 0.028). Furthermore, the k-means cluster analysis showed that high mRNA expression of EED, SUZ12 and EZH2 was significantly correlated with the aggressive clinical behavior and poor prognosis.

Conclusions

High expression of EED, SUZ12 and EZH2 might contribute to the CRC development/progression.

Balasubramanian S, Lee K, Adhikary G, Gopalakrishnan R, Rorke EA, Eckert RL (2008) The Bmi-1 polycomb group gene in skin cancer: regulation of function by (-)-epigallocatechin-3-gallate. Nutr Rev 66(Suppl 1):S65–S68. doi:10.1111/j.1753-4887.2008.00071.x CrossRefPubMedCentralPubMed

Brait M, Sidransky D (2011) Cancer epigenetics: above and beyond. Toxicol Mech Methods 21:275–288. doi:10.3109/15376516.2011.562671 CrossRefPubMedCentralPubMed

Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT (2007) EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67:547–556. doi:10.1002/pros.20550 CrossRefPubMed

Cao R, Zhang Y (2004) SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 15:57–67. doi:10.1016/j.molcel.2004.06.020 CrossRefPubMed

Cao R et al (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298:1039–1043. doi:10.1126/science.1076997 CrossRefPubMed

Cao W et al (2011) EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia. Cancer Prev Res 4:1816–1824. doi:10.1158/1940-6207.CAPR-11-0130 CrossRef

Cao W et al (2012) EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS ONE 7:e52984. doi:10.1371/journal.pone.0052984 CrossRefPubMedCentralPubMed

Cui B, Tao J, Yang Y (2012) Studies on the expression patterns of class I PI3K catalytic subunits and its prognostic significance in colorectal cancer. Cell Biochem Biophys 62:47–54. doi:10.1007/s12013-011-9257-6 CrossRefPubMed

Cui Y, Chen J, He Z, Xiao Y (2013) SUZ12 depletion suppresses the proliferation of gastric cancer cells. Cell Physiol Biochem 31:778–784. doi:10.1159/000350095 CrossRefPubMed

Denisenko O, Shnyreva M, Suzuki H, Bomsztyk K (1998) Point mutations in the WD40 domain of Eed block its interaction with Ezh2. Mol Cell Biol 18:5634–5642PubMedCentralPubMed

Eskander RN, Ji T, Huynh B, Wardeh R, Randall LM, Hoang B (2013) Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer 23:997–1005. doi:10.1097/IGC.0b013e318296a265 CrossRefPubMedCentralPubMed

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917. doi:10.1002/ijc.25516 CrossRefPubMed

Fluge O et al (2009) Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 101:1282–1289. doi:10.1038/sj.bjc.6605333 CrossRefPubMedCentralPubMed

Fussbroich B et al (2011) EZH2 depletion blocks the proliferation of colon cancer cells. PLoS ONE 6:e21651. doi:10.1371/journal.pone.0021651 CrossRefPubMedCentralPubMed

Gong Y et al (2011) Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117:5476–5484. doi:10.1002/cncr.26179 CrossRefPubMed

Hammoud SS, Cairns BR, Jones DA (2013) Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol 25:177–183. doi:10.1016/j.ceb.2013.01.007 CrossRefPubMedCentralPubMed

Hu S et al (2010) Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 10:788–795CrossRefPubMed

Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K (2010) Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 39:761–772. doi:10.1016/j.molcel.2010.08.013 CrossRefPubMedCentralPubMed

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. doi:10.3322/caac.20107 CrossRefPubMed

Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692. doi:10.1016/j.cell.2007.01.029 CrossRefPubMedCentralPubMed

Khare S, Verma M (2012) Epigenetics of colon cancer. Methods Mol Biol 863:177–185. doi:10.1007/978-1-61779-612-8_10 CrossRefPubMed

Kim JH et al (2004) The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203:217–224CrossRefPubMed

Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD, Orkin SH (2013) Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol 9:643–650. doi:10.1038/nchembio.1331 CrossRefPubMedCentralPubMed

Kodach LL et al (2010) The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Carcinogenesis 31:1567–1575. doi:10.1093/carcin/bgq147 CrossRefPubMedCentralPubMed

Ku M et al (2008) Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 4:e1000242. doi:10.1371/journal.pgen.1000242 CrossRefPubMedCentralPubMed

Li DW et al (2010) Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol 136:997–1006. doi:10.1007/s00432-009-0745-7 CrossRefPubMed

Li H et al (2012) SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol Cancer Res 10:1462–1472. doi:10.1158/1541-7786.MCR-12-0335 CrossRefPubMedCentralPubMed

Lin YW, Chen HM, Fang JY (2011) Gene silencing by the Polycomb group proteins and associations with cancer. Cancer Invest 29:187–195. doi:10.3109/07357907.2010.512605 CrossRefPubMed

Liu C, Shi X, Wang L, Wu Y, Jin F, Bai C, Song Y (2014) SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis. Tumour Biol 35:6073–6082. doi:10.1007/s13277-014-1804-5 CrossRefPubMed

Martin-Perez D et al (2010) Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. Am J Pathol 177:930–942. doi:10.2353/ajpath.2010.090769 CrossRefPubMedCentralPubMed

Novak K (2004) Epigenetics changes in cancer cells. MedGenMed 6:17PubMedCentralPubMed

Pietersen AM et al (2008) EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 10:R109. doi:10.1186/bcr2214 CrossRefPubMedCentralPubMed

Piunti A, Pasini D (2011) Epigenetic factors in cancer development: polycomb group proteins. Future Oncol 7:57–75. doi:10.2217/fon.10.157 CrossRefPubMed

Richly H, Aloia L, Di Croce L (2011) Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis 2:e204. doi:10.1038/cddis.2011.84 CrossRefPubMedCentralPubMed

Rodenhiser DI (2009) Epigenetic contributions to cancer metastasis. Clin Exp Metastasis 26:5–18. doi:10.1007/s10585-008-9166-2 CrossRefPubMed

Sato T et al (2013) PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep 3:1911. doi:10.1038/srep01911 PubMedCentralPubMed

Seo GS et al (2013) EED gene polymorphism in patients with colorectal cancer. Int J Biol Markers 28:274–279. doi:10.5301/JBM.5000024 CrossRefPubMed

Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31:27–36. doi:10.1093/carcin/bgp220 CrossRefPubMedCentralPubMed

Shen L, Cui J, Liang S, Pang Y, Liu P (2013) Update of research on the role of EZH2 in cancer progression. Onco Targets Ther 6:321–324. doi:10.2147/OTT.S42453 CrossRefPubMedCentralPubMed

Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647:21–29. doi:10.1016/j.mrfmmm.2008.07.010 CrossRefPubMed

Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6:846–856. doi:10.1038/nrc1991 CrossRefPubMed

Tan JZ, Yan Y, Wang XX, Jiang Y, Xu HE (2014) EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol Sin 35:161–174. doi:10.1038/aps.2013.161 CrossRefPubMedCentralPubMed

Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S (2010) EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol 16:2421–2427CrossRefPubMedCentralPubMed

Wang J, Ma ZB, Li K, Guo GH (2014) Association between EZH2 polymorphisms and colorectal cancer risk in Han Chinese population. Med Oncol 31:874. doi:10.1007/s12032-014-0874-y CrossRefPubMed

Wolters T, Vissers KJ, Bangma CH, Schroder FH, van Leenders GJ (2010) The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy. BJU Int 106:280–286. doi:10.1111/j.1464-410X.2009.08998.x CrossRefPubMed

Yin T et al (2011) Bmi-1 promotes the chemoresistance, invasion and tumorigenesis of pancreatic cancer cells. Chemotherapy 57:488–496. doi:10.1159/000334103 CrossRefPubMed

Yoo KH, Hennighausen L (2012) EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci 8:59–65CrossRefPubMedCentralPubMed

Yu H et al (2012) PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ. PLoS ONE 7:e51239. doi:10.1371/journal.pone.0051239 CrossRefPubMedCentralPubMed

Title: Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer
Authors: Yan-Long Liu
Xu Gao
Yang Jiang
Gan Zhang
Zi-Cheng Sun
Bin-Bin Cui
Yan-Mei Yang
Publication date: 01-04-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 4/2015
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1854-5

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

ACC 2024 Congress

Springer Medicine

Abstract

Background and objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2015

Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients

Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines

The plasma level of retinol, vitamins A, C and α-tocopherol could reduce breast cancer risk? A meta-analysis and meta-regression

Metabolomic profiling of human serum in lung cancer patients using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry and gas chromatography/mass spectrometry